Physician profile
Onyinye E Okezie
NPI 1952415838
$1,260.21
in general payments reported to CMS, 2019-2025
12 companies · $253 in 2025
The $253 reported for 2025 was more than what 80% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $120 · 2021: $91.12 · 2022: $84.63 · 2023: $186 · 2024: $316 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $755.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $291.80 | 2019-2025 | Pediarix, Bexsero, Rotarix |
| Sanofi Pasteur INC. | $208.90 | 2019-2025 | |
| Verrica Pharmaceuticals INC. | $203.61 | 2024-2025 | Ycanth |
| Pfizer INC. | $154.04 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $134.76 | 2019-2025 | M-M-R II, Gardasil 9, Vaxneuvance |
| Phadia US INC. | $78.14 | 2021-2025 | Immunocap |
| Sobi, INC | $63.04 | 2020-2024 | |
| Cranial Technologies, INC | $54.74 | 2024-2025 | Doc Band |
| Alk-Abello, INC | $20.87 | 2024 | Odactra, Grastek, Ragwitek |
| Kowa Pharmaceuticals America, INC. | $20.61 | 2025 | Zoryve |
| Lnhc, INC | $15.15 | 2025 | Zelsuvmi |
| Seqirus USA INC | $14.55 | 2025 | Flucelvax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Onyinye Okezie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.